StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) company profile

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.18−0.23 (-5.22%)

Close on Nov 17, 2026Market cap $103.61MP/E –Yield –

About Lexaria Bioscience

Pharmaceutical Preparations, SIC 2834

Lexaria Bioscience Corp. is a biotechnology company that develops drug delivery formulations designed to improve the bioavailability of active pharmaceutical ingredients. Its primary technology, DehydraTECH, combines active molecules with fatty acid-rich triglyceride oils to facilitate absorption into the bloodstream through oral ingestion. The technology is utilized across pharmaceutical, nutraceutical, consumer packaged goods, and over-the-counter product categories, addressing indications such as diabetes, weight loss, hypertension, and epilepsy. Lexaria operates primarily by licensing its patented technology to corporate partners and industry participants who integrate DehydraTECH into developmental and commercial products, including oral pouches, capsules, tablets, foods, and beverages.

The company maintains an intellectual property portfolio of 56 granted or allowed patents worldwide, with active licensing agreements and operations extending across the United States, Australia, Japan, South Africa, and Europe. Lexaria conducts clinical research programs internationally, including clinical trials sponsored in Australia. The provided text does not disclose the location of the company's headquarters.

Summary of the business section of Lexaria Bioscience's latest annual report, written by StockData.

Company profile

Company

Legal name
Lexaria Bioscience Corp.
Headquarters
Kelowna, A1
Address
100 - 740 Mccurdy Road V1X 2P7
Phone
(250) 765-6424
Employees
134, Aug 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
August 31
Auditor
MaloneBailey, LLP, Houston, Texas

Stock & identifiers

Ticker
LEXX
Former tickers
LXRP until Jul 15, 2021
Exchange
Nasdaq
IPO date
Oct 11, 2007
Shares outstanding
25M, Jul 13, 2026
Public float
$24.60M, Feb 28, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Aug 3, 2026; 1-for-30 reverse, Jan 14, 2021
SEC CIK
1348362
FIGI
BBG000JQHT18
Share class FIGI
BBG001SBJ1Q1
EIN
20-2000871

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Richard ChristopherChief Executive Officer, Director65,000
John Martin DochertyPresident & CSO, Director59,451
Vanessa CarleSecretary750
Michael Elliot ShankmanChief Financial Officer–
Christopher BunkaDirector555,455
William Edward McKechnieDirector18,191
Albert L. Reese JrDirector10,917
Nicholas W. BaxterDirector11,000
Baljinder BhullarDirector13,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$893.30K$496.75K$385.95K$-77490–
FY2024$1.40M$1.67M$296.33K$272380–
FY2023$287.63K$156.94K$237.19K$-64530–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Richard Christopher
Chief Executive Officer
$460.82K$25.90K–$93.02K$32.78K$612.52K+18%
Christopher Bunka
Chairman, Former CEO
–$56.78K$224.00K––$280.78K-68%
John Docherty
President & CSO
$332.35K$98.13K–$93.02K–$523.50K+26%
Michael Shankman
Chief Financial Officer
$123.07K$4.08K–$117.18K$4.08K$248.39K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“The IND application was supported by the results of Lexaria’s five investigator-initiated human clinical studies of its DehydraTECH-CBD which were conducted between 2018-2023, in an aggregate total of 134 people, without recording a single serious adverse event (the “HYPER Studies”).”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 10, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 6, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 14, 2026DelistingNotice of delisting from exchange (Form 25)
Oct 18, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 23, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 28, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 11, 2021ListingRegistration of securities on an exchange (Form 8-A)
Dec 31, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 10, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 5, 2018MergerRegistration of securities for a merger or exchange offer (S-4)
Nov 2, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 12, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
May 11, 2016Name changeName changed from LEXARIA CORP. to Lexaria Bioscience Corp.
Dec 10, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 1, 2014Late filingNotification of late filing
Dec 1, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 23, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 10, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 11, 2007IPOInitial public offering priced (424B4 prospectus)
Sep 20, 2006Auditor changeChange in certifying accountant (8-K Item 4.01)

See a number that looks wrong?